These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: [Effect of vasoactive intestinal peptide on defecation and VIP-cAMP-PKA-AQP3 signaling pathway in rats with constipation]. Author: Zhou Y, Wang Y, Zhang H, Yan S, Wang B, Xie P. Journal: Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Nov 28; 41(11):1175-1180. PubMed ID: 27932763. Abstract: To observe the effect of vasoactive intestinal peptide (VIP) on the metabolism of intestinal fluid and cyclic AMP protein kinase A signaling pathway (cAMP-PKA) and water channel protein 3 (AQP3) in rats with constipation, and to explore the mechanism of VIP in the treatment of constipation. Methods: A total of 45 healthy adult rats were randomly divided into a control group, a model group, a model +VIP group. After 4 weeks of VIP treatment, the first black stool time were examined with the ink gastric method; the water content in feces was calculated; the morphological changes in colonic tissues were observed by HE staining. The expression of VIP and AQP3 protein levels in colon tissues were detected by Western blot; and the cAMP, PKA, AQP3 mRNA expression levels were detected by quantitative real time polymerase chain reaction (qPCR). Results: Compared with the control group, the first black stool time was prolonged, the water content of fecal decreased significantly (both P<0.01); part of the colon mucosa epithelial cells were destructed; the goblet cell volume decreased and quantity was reduced; the contents of AQP3 and VIP in colon tissues were significantly decreased, and the cAMP, PKA and AQP3 mRNA levels were decreased in the model group (all P<0.05). Compared with the model group, the first black stool time in the model +VIP group was shortened, the fecal water content increased significantly (both P<0.05); the mucosal epithelium integrity improved, the number of goblet cells increased; the content of AQP3 and VIP in colon tissues was increased, and the cAMP, PKA, and AQP3 mRNA levels were elevated (all P<0.05). Conclusion: Intravenous injection of VIP can regulate intestinal fluid metabolism and improve the symptoms of constipation in rats, which might be related to the regulation of VIP-cAMP-PKA-AQP3 signaling pathway. 目的:观察血管活性肠肽(vasoactive intestinal peptide,VIP)对便秘大鼠肠道水液代谢、环磷酸腺苷-蛋白激酶A信号通路(cyclic AMP protein kinase A signaling pathway,cAMP-PKA)和水通道蛋白3(water channel protein 3,AQP3)的影响,探讨VIP治疗便秘的作用及机制。方法:45只健康成年Sprague-Dawley大鼠随机分为空白对照组、模型组、模型+ VIP组。给药4周后,墨汁灌胃法检测大鼠首粒黑便排出时间;根据大鼠粪便干湿重计算粪便含水率;HE染色观察各组大鼠结肠组织形态学变化;Western 印迹检测各组大鼠结肠组织中 VIP和AQP3蛋白表达水平;定量即时聚合酶链锁反应(quantitative real time polymerase chain reaction,qPCR)检测各组大鼠结肠组织中cAMP,PKA和AQP3 mRNA的表达水平。结果:与空白对照组比较,模型组大鼠首粒黑便出现时间延长,粪便含水率明显减少(均P<0.01);结肠黏膜上皮部分破坏,杯状细胞体积减小,数量明显减少;结肠组织中VIP和AQP3蛋白含量明显减少,AQP3,cAMP和PKA mRNA相对表达水平均有所降低(均P<0.05)。与模型组比较,模型+VIP组大鼠首粒黑便出现时间缩短,粪便含水率明显增加(均P<0.05);结肠黏膜上皮完整性明显改善,杯状细胞体积增大,数量增多;结肠组织中VIP和 AQP3蛋白含量增多,CAMP,PKA和AQP3 mRNA相对表达水平升高(均P<0.05)。结论:VIP静脉注射能够调节肠道水液代谢,改善大鼠便秘症状,其机制可能与调节VIP-cAMP-PKA-AQP3信号通路有关。.[Abstract] [Full Text] [Related] [New Search]